Investigation of the anti-inflammatory, hypoglycemic activity and median lethal dose (LD50) level of limonene in mice and rats

Creative Commons License


Acta Pharmaceutica Sciencia, vol.56, no.1, pp.85-94, 2018 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 56 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.23893/1307-2080.aps.05606
  • Journal Name: Acta Pharmaceutica Sciencia
  • Journal Indexes: Scopus
  • Page Numbers: pp.85-94
  • Keywords: Anti-inflammatory activity, Hypoglycemic activity, Limonene, Median lethal dose, Mice, Rats
  • Istanbul Medipol University Affiliated: Yes


The aim of this study is to investigate the anti-inflammatory, hypoglycemic activity and median lethal lose (LD50) level of limonene mice and rats. Lethal dose levels were investigated using the probit analysis method. For the measurement of anti-inflammatory activity, seven separate work groups were established and limonene was administered in three different doses 0.15, 0.30, 0.60 mL/ kg. Indomethacin and etodolac were used as reference anti-inflammatory agents. For the evaluation of hypoglycemic activity, 6 separate work groups, consisting of healthy and diabetic mice were established and glibenclamide was used as the reference agent. The LD50 level of limonene was determined to be 2.77 mL/kg. It is determined that all administered dosages of limonene possess anti-inflammatory activity; among these, 0.30 mL/kg was equivalent to indomethacin, and the remaining dosages were equivalent to etodolac. No hypoglycemic activity of limonene was observed in healthy and diabetic mice. As a consequence, it is concluded that limonene did not show hypoglycemic activity, but possessed a strong anti-inflammatory activity.